---
title: "Redhill Biopharma (RDHL) news: offering"
url: "https://aibio.space/companies/redhill-biopharma/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "RDHL offering news: Redhill Biopharma signs $6 million private placement, up to $19.4 million with warrants. Redhill Biopharma Ltd. (NASDAQ: RDHL), Israel."
---

RDHL Redhill Biopharma Ltd. NASDAQ · Israel

# Redhill Biopharma (RDHL) news RDHL offering news

Listings · 2026-10-07

## [Redhill Biopharma gets 180 more days on Nasdaq bid price, to April 5, 2027](https://aibio.space/news/redhill-biopharma-gets-180-more-days-nasdaq-bid-price-april-5-2027/)

Nasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025.

## Latest Redhill Biopharma news

1. 2026-06-18 Financings [Redhill Biopharma signs $6 million private placement, up to $19.4 million with warrants](https://aibio.space/news/redhill-biopharma-signs-6-million-private-placement-up-19-4-million/) Redhill Biopharma agreed on June 18, 2026 to sell 8,571,429 ADSs at $0.70 each with two series of warrants. The upfront money is about $6 million, and the warrants add about $13.4 million only if they are exercised for cash, which the company says is not assured.

## Redhill Biopharma at a glance

- **Ticker**: RDHL

- **Listing**: NASDAQ

- **Country**: Israel

- **Cash, Jun 30, 2025**: $2.9 million

### Related companies

- [Rekah Pharmaceutical Industry](https://aibio.space/companies/rekah-pharmaceutical-industry/) TASE: REKA
- [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NASDAQ: NRSN
- [SciSparc](https://aibio.space/companies/scisparc/) NASDAQ: SPRC
- [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) AMEX: NSRX
- [Entera Bio](https://aibio.space/companies/entera-bio/) NASDAQ: ENTX
- [BioLineRX](https://aibio.space/companies/biolinerx/) TASE: BLRX
- [Can-Fite BioPharma](https://aibio.space/companies/can-fite-biopharma/) TASE: CANF
- [PolyPid](https://aibio.space/companies/polypid/) NASDAQ: PYPD

### Also on NASDAQ

- [HARVARD BIOSCIENCE INC](https://aibio.space/companies/harvard-bioscience/) HBIO
- [Vanda Pharmaceuticals](https://aibio.space/companies/vanda-pharmaceuticals/) VNDA
- [PepGen](https://aibio.space/companies/pepgen/) PEPG
- [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) LRMR
- [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA
- [Recursion Pharmaceuticals](https://aibio.space/companies/recursion-pharmaceuticals/) RXRX

## Redhill Biopharma annual financials

| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | [$8.0 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) | [$6.5 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) |
| Research and development | [$1.6 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) |
| Net income (loss) | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) | [$23.9 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) |
| Cash from operations | [-$9.4 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) | [-$35.8 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/) |
| Cash and equivalents | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025011883/) | [$5.6 million](https://www.sec.gov/Archives/edgar/data/1553846/000155837025011883/) |

Latest balance sheet, Jun 30, 2025 (6-K): cash and equivalents $2.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Redhill Biopharma

Has Redhill Biopharma raised money recently?

Our latest story on this, dated Jun 18, 2026: "Redhill Biopharma signs $6 million private placement, up to $19.4 million with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/redhill-biopharma-signs-6-million-private-placement-up-19-4-million/).

What is the ticker symbol of Redhill Biopharma?

Redhill Biopharma Ltd. trades under the ticker RDHL on NASDAQ.

Where is Redhill Biopharma listed?

Redhill Biopharma Ltd. is listed on NASDAQ.

What is the SEC CIK of Redhill Biopharma?

The SEC Central Index Key (CIK) for Redhill Biopharma Ltd. is 1553846. Its filings are on SEC EDGAR.

How many shares does Redhill Biopharma have outstanding?

50,923,261,000 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-27.

Which country or territory is Redhill Biopharma listed under?

Our directory records Redhill Biopharma Ltd. under Israel.

What does Redhill Biopharma do?

Our directory classifies Redhill Biopharma Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Redhill Biopharma?

The ISIN recorded for Redhill Biopharma Ltd. is US7574683014.

Does aibio.space cover Redhill Biopharma?

aibio.space lists Redhill Biopharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Redhill Biopharma incorporated?

SEC records list its state or country of incorporation as L3.

What was Redhill Biopharma's revenue last year?

$8.0 million for the fiscal year ended Dec 31, 2024, as reported to the SEC.

Is Redhill Biopharma profitable?

Redhill Biopharma Ltd. reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2024, and used $9.4 million of cash in operations, per its annual report to the SEC.

How much does Redhill Biopharma spend on research and development?

$1.6 million in the fiscal year ended Dec 31, 2024, per its annual report.

How much cash does Redhill Biopharma have?

$2.9 million in cash at Jun 30, 2025, per its 6-K.

What is the latest Redhill Biopharma (RDHL) stock news?

Our latest story on Redhill Biopharma, dated Oct 7, 2026: "Redhill Biopharma gets 180 more days on Nasdaq bid price, to April 5, 2027". Nasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025. [Source](https://aibio.space/news/redhill-biopharma-gets-180-more-days-nasdaq-bid-price-april-5-2027/).

## Investor discussion: Redhill Biopharma

Members talk about Redhill Biopharma (RDHL). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Redhill Biopharma, newest first. Each line links the filing it comes from.

1. 2026-10-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004732/zk2636207.htm)
2. 2026-06-18 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891326003248/zk2635574.htm)
3. 2026-05-27 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891326002944/zk2635182.htm)
4. 2026-04-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891326002107/zk2635072.htm)
5. 2025-12-23 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891325004101/exhibit_99-1.htm)
6. 2025-12-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891325003972/zk2534077.htm)
7. 2025-10-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891325003524/exhibit_99-1.htm)
8. 2025-09-05 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000155837025011883/rdhl-20250630xex99d1.htm)
9. 2025-08-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891325002880/zk2533655.htm)
10. 2025-04-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1553846/000117891325001321/zk2533028.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RDHL on TradingView](https://www.tradingview.com/symbols/NASDAQ-RDHL/).

## SEC filings and registration

- **SEC name**: RedHill Biopharma Ltd.

- **CIK**: 1553846

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: RDHL (Nasdaq)

- **State or country of incorporation**: L3

- **Filer category**: Non-accelerated filer

- **Business address**: 21 HA'ARBA'A STREET, TEL AVIV, Israel, 64739

- **Phone**: 972-3-541-3131

- **Shares outstanding**: 50,923,261,000 as of 2025-12-31 (20-F filed 2026-04-27)

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004808/zk2636244.htm) filed 2026-10-21
- [6-K](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004786/zk2636236.htm) filed 2026-10-19
- [6-K](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004765/zk2636223.htm) filed 2026-10-13
- [424B5](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004763/zk2636216.htm) filed 2026-10-13
- [6-K](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004732/zk2636207.htm) filed 2026-10-07
- [6-K](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004678/zk2636177.htm) filed 2026-09-30
- [6-K](https://www.sec.gov/Archives/edgar/data/1553846/000110465926112334/rdhl-20260630x6k.htm) filed 2026-09-30
- [6-K](https://www.sec.gov/Archives/edgar/data/1553846/000117891326004369/zk2636058.htm) filed 2026-09-01

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001553846), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Redhill Biopharma Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RDHL, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Redhill Biopharma Ltd.

- **Ticker**: RDHL

- **Listing**: NASDAQ

- **Country or territory**: Israel

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US7574683014

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RDHL/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/redhill-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Redhill Biopharma (RDHL) news: offering", 2026-10-31, https://aibio.space/companies/redhill-biopharma/